Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 5/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17778665 | 1.00 | PIK3C3 (0.41) | PIK3C3IRAK4WDR5BRD4CREBBP | |
| SCHEMBL17778912 | 0.90 | IRAK4 (0.35) | PIK3C3IRAK4MAPK1KCNH2CSNK1D | |
| SCHEMBL19689781 | 0.90 | IRAK4 (0.35) | PIK3C3IRAK4MAPK1KCNH2CSNK1D | |
| SCHEMBL17778744 | 0.87 | RAF1 (0.39) | PIK3C3IRAK4KCNH2 | |
| SCHEMBL19689811 | 0.86 | DYRK1A (0.42) | PIK3C3IRAK4MAPK1KCNH2 | |
| SCHEMBL17778803 | 0.86 | DYRK1A (0.42) | PIK3C3IRAK4MAPK1KCNH2 | |
| SCHEMBL17778914 | 0.84 | DYRK1A (0.43) | IRAK4 | |
| SCHEMBL16754282 | 0.84 | KARS1 (0.40) | MAPK1SYK | |
| SCHEMBL17778323 | 0.84 | KARS1 (0.40) | MAPK1SYK | |
| SCHEMBL17778806 | 0.84 | MEN1 (0.43) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3C3 4720/4885IRAK4 2889/4885WDR5 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.